Personalized Treatment Algorithms for Difficult-to-treat Asthma
Summary
Asthma is a common, complex and costly chronic condition. Moreover, asthma is heterogeneous in terms of treatment response. This heterogeneity contributes to the difficulty in both studying and treating asthma. This is a pilot study to improve health outcomes in youths with difficult to treat asthma with ongoing symptoms and healthcare utilization despite medium to high doses of inhaled corticosteroids. Asthma heterogeneity in both disease pathophysiology and treatment response contributes to the difficulty in both studying and managing asthma. In order to begin to develop personalized algorithms for patients, investigators need to model novel biomarkers and other factors that contribute to individual differences in asthma outcome and test other factors that contribute to individual differences in asthma outcome and test personalized treatment strategies.
Timeline
- Start
- 2018-03-16
- Primary completion
- 2019-10-03
- Completion
- 2019-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | — | Oral |
| Subject | Beclomethasone | Small molecule | — | — |
| Subject | Budesonide/Formoterol | Unknown | — | — |
| Subject | Cetirizine | Other / unclassified | — | Oral |
| Subject | Cholecalciferol | Other / unclassified | — | Oral |
| Subject | Fluticasone | Other / unclassified | — | — |
| Subject | Fluticasone propionate | Other / unclassified | — | Intranasal |
| Subject | Fluticasone/Salmeterol | Unknown | — | — |
| Subject | Loratadine | Small molecule | — | Oral |
| Subject | Mometasone furoate | Other / unclassified | — | — |
| Subject | Mometasone/Formoterol | Unknown | — | — |
| Subject | Tiotropium | Other / unclassified | — | — |